A randomized controlled trial to evaluate the effectiveness of adjuvant chemotherapy using FOLFOX to prevent recurrence after curative radiofrequency ablation of liver metastasis from colorectal carcinoma

A randomized controlled trial to evaluate the effectiveness of adjuvant chemotherapy using FOLFOX to prevent recurrence after curative radiofrequency ablation of liver metastasis from colorectal carcinoma - A randomized controlled trial for adjuvant FOLFOX therapy after radiofrequency ablation of liver metastasis from colorectal carcinoma.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000360

Enrollment

190

Registered

2006-06-01

Start date

2006-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cases with liver metastasis from colorectal carcinoma, which is removed curatively by radiofrequency ablation

Interventions

Parenterally administration of mFOLFOX6 for 12 courses after curative radoiofrequency ablation of liver metastasis from colorectal carcinoma Only follow-up without any anti-cancer therapy after curat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients undergoing curative radiofrequency ablation for liver metastasis (max 5cm and 5 nodules) from colorectal carcinoma. No residual disease by CT or MRI image after radiofrequency ablation and no disease except for liver metastasis and the primary colorectal carcinoma is resected.

Exclusion criteria

Exclusion criteria: The patients with other malignant disease, non-curative radiofrequency ablation

Design outcomes

Primary

Measure	Time frame
Liver metastasis disease-free survival	—

Secondary

Measure	Time frame
Disease-free survival Overall survival Side effect	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026